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Abstract: Access to antiretroviral therapy (ART) is improving worldwide. Immune reconstitution 
inflammatory syndrome (IRIS) is a common complication of ART initiation. In this review, we 
provide an overview of clinical and epidemiological features of HIV-associated IRIS, current 
understanding of pathophysiological mechanisms, available therapy, and preventive strategies. 
The spectrum of HIV-associated IRIS is described, with a particular focus on three important 
pathogen-associated forms: tuberculosis-associated IRIS, cryptococcal IRIS, and Kaposi’s 
sarcoma IRIS. While the clinical features and epidemiology are well described, there are major 
gaps in our understanding of pathophysiology and as a result therapeutic and preventative 
strategies are suboptimal. Timing of ART initiation is critical to reduce IRIS-associated mor-
bidity. Improved understanding of the pathophysiology of IRIS will hopefully enable improved 
diagnostic modalities and better targeted treatments to be developed.
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Introduction
Antiretroviral therapy (ART) has dramatically reduced HIV-associated mortality, 
which decreased from a peak of 2.3 million in 2005 to 1.6 million in 2012.1–3 This 
reflects improvement in access to ART in the last decade, especially for HIV-infected 
patients in low- and middle-income countries, where the number of patients receiving 
ART has increased more than 30-fold (from 300,000 in 2002 to 9.7 million in 2012) 
and life expectancy is increasing.3,4 It is now recognized that commencement of ART 
earlier in HIV infection improves outcomes, and international guidelines have been 
updated to reflect this.5 Tuberculosis (TB) is now considered to be an indication for 
ART irrespective of CD4 count, as ART reduces mortality in TB patients.6
However, ART initiation is not without risk of complications, particularly in the 
first 6 months.7,8 HIV-associated immune reconstitution inflammatory syndrome (IRIS) 
has emerged as an important early complication of ART initiation, associated with 
considerable morbidity and mortality, particularly in patients who commence ART with 
advanced immunosuppression.9 In this condition, immune recovery following ART 
initiation associates with a pathological inflammatory response, usually directed toward 
microbial antigens. Although there is considerable clinical and pathophysiological 
heterogeneity, key features include clinical deterioration in the first weeks to months 
of ART, with evidence of localized tissue inflammation with or without a systemic 
inflammatory response.
In this review, we provide an overview of clinical and epidemiological features of 
HIV-associated IRIS, current understanding of pathophysiological mechanisms, available 
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therapy, and preventive strategies, with a particular focus on 
three important pathogen-associated forms: TB-associated IRIS 
(TB-IRIS), cryptococcal IRIS (C-IRIS), and Kaposi’s sarcoma 
(KS) IRIS. A key message is that while IRIS- associated mor-
bidity may be considerable, ART is key to survival in HIV and 
timing of initiation of ART is critical. Rarely should ART be 
interrupted or discontinued because of IRIS.
Our discussion is limited to HIV-associated forms of 
IRIS. However, IRIS has been described following reversal of 
other forms of immunosuppression, including after reversal 
of iatrogenic immunosuppression in transplant recipients, 
following bone marrow recovery after chemotherapy for 
hematological malignancies, and following discontinuation 
of anti-tumor necrosis factor-α (TNF-α) therapy for rheu-
matoid arthritis or treatment with the monoclonal antibody 
natalizumab for multiple sclerosis.10–13
Historical perspective and case 
definitions
Among the first accounts of IRIS-type phenomena were 
reports of zidovudine-induced fever associated with lymph-
adenitis in patients with nontuberculous mycobacterial 
infections.14,15 French et al reported a case series of unusu-
ally localized Mycobacterium avium-intracellulare (MAI) 
infections presenting with fevers and lymphadenitis without 
mycobacteraemia, which developed soon after commence-
ment of zidovudine monotherapy.16 These presentations were 
accompanied by the emergence of delayed-type hypersensitiv-
ity reactivity to purified protein derivative (PPD) in patients 
who had previously been PPD unresponsive.
IRIS has emerged as a highly heterogeneous condition, 
with features differing according to the associated pathogen. 
However, two distinct temporal patterns of disease were 
commonly described and are now recognized as “paradoxical 
IRIS” and “unmasking IRIS” (see Figure 1).17–19 In paradoxi-
cal forms of IRIS, symptoms and signs associated with a 
known opportunistic infection (OI), for which treatment is 
under way, recur or become acutely worse, despite an earlier 
favorable response to therapy prior to ART. In unmasking 
IRIS, a new OI presents with a pronounced inflammatory 
component following ART initiation. Responding to clinical 
and research needs, the International Network for the Study 
of HIV-associated IRIS (INSHI) published consensus case 
definitions for C-IRIS and TB-IRIS.18,19 Such definitions 
are suitable for use in low-resource settings, as CD4 count 
and HIV viral load responses are not included as criteria. 
Consensus case definitions for other forms of IRIS are lack-
ing although much needed.20 The main challenge with all 
proposed definitions of paradoxical IRIS is the requirement 
to adequately exclude other causes of clinical deterioration. 
There is no definitive diagnostic test for IRIS. In resource-
constrained settings, clinicians may find themselves treating 
multiple conditions concurrently in a sick patient, being 
uncertain of the definitive diagnosis due to limited labora-
tory support, with IRIS as a diagnosis of exclusion following 
unsuccessful treatment of other conditions.
The concept of unmasking IRIS is less well defined than 
that of paradoxical IRIS. The broader term of an “ART-
associated OI” is proposed to encompass all OI diagnosed 
during early ART, as unmasking IRIS may be difficult to 
differentiate from development of an OI in a patient who is 
still immunocompromised during early ART and which pro-
gresses along a typical clinical course (see Figure 1). Some 
recent reports have defined all new OI in the first 6 months 
of ART as cases of unmasking IRIS.21,22 This approach may 
reduce comparability with earlier studies and increase het-
erogeneity of IRIS cases, complicating efforts to precisely 
define IRIS immunopathology.23
Epidemiology and risk factors
Numerous infective and noninfective conditions are 
associated with IRIS in HIV infection (see Table 1).15,24–34 
A meta-analysis of 54 studies (published between 1998 and 
2009) of 13,103 HIV-infected patents starting ART, reported 
1,699 (13%) cases of IRIS.9 The incidence was slightly higher 
(16.1%) in studies of unselected HIV-infected patients, and 
reported incidence varied widely depending on study design, 
population, and associated pathogen. For example, 37.7% 
of patients with a diagnosis of cytomegalovirus (CMV ) 
retinitis prior to ART initiation developed IRIS, compared 
to 6.4% patients with a diagnosis of KS.9
The epidemiology of IRIS reflects the epidemiological 
distribution of HIV-associated OI and the prevalence of vari-
ous key risk factors in a given population. Table 2 reports the 
proportion of IRIS attributable to different OI/inflammatory 
conditions in recently published studies of unselected patients 
commencing ART, demonstrating that reported incidence var-
ies according to geographic region and by study design.7,21,35–38 
Risk factors for IRIS include an advanced state of immu-
nosuppression (low CD4 count) and high infective antigen 
burden/disseminated OI at ART initiation (see Table 3). These 
characterize a substantial proportion of patients with newly 
diagnosed HIV in developing countries where suboptimal 
access to HIV care and health services in general, and stigma 
associated with HIV, contribute to late presentation.39 While 
advanced immunosuppression and late presentation are also 
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encountered in patients presenting to ART services in higher-
resource settings, in low-resource settings IRIS incidence and 
associated mortality appear to be higher.8,40
Overall mortality in IRIS is reported to be between 0% 
and 15%, with variability attributed to geography, associ-
ated OI, baseline morbidity, and degree of immunosup-
pression.9,40,41 IRIS affecting the central nervous system 
(CNS) confers a particularly high mortality. In patients with 
cryptococcal meningitis (CM)-associated IRIS, mortality is 
reported at 20.8% and CNS TB-IRIS mortality rates are up to 
75%.9,42,43 Where space is limited around a critical organ, such 
as the brain, excess inflammation with associated cerebral 
edema has severe effects. Establishing an accurate cause of 
death and correctly attributing it to IRIS is difficult in many 
circumstances and reported mortality rates may therefore 
be under- or overestimates. High rates of mortality occur in 
the first 6 months of ART in resource-limited settings, even 
in patients without an IRIS diagnosis. There is difficulty 
determining from available data sources what the exact 
contribution of IRIS to these deaths is.8,38,44
Pathophysiology
In both C-IRIS and TB-IRIS, at the time of IRIS onset, elevated 
concentrations of proinflammatory mediators, including C-reac-
tive protein (CRP) and cytokines (eg, interleukin [IL]-6, IL-12, 
TNF-α) are detectable in serum and may also be elevated in 
cerebrospinal fluid (CSF) in CM-IRIS and TB meningitis (TBM) 
IRIS.45–49 A proinflammatory cytokine cascade may be a final 
common pathway by which IRIS inflammation occurs.45,50
The increased incidence of IRIS in patients with lower 
pre-ART CD4 counts and disseminated OI suggests that 
more advanced immunodeficiency prior to ART initiation 
may lead to a higher pathogen load, resulting in excessive 
inflammation, once the immune system starts to recover. For 
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Figure 1 Schematic demonstrating sequence of key events in paradoxical immune reconstitution inflammatory syndrome (IRIS) (A) and unmasking IRIS (B).
Note: Unmasking IRIS is one possible presentation of an antiretroviral therapy (ART)-associated opportunistic infection (OI), and is characterized by an atypically inflammatory 
or localized presentation, unlike other forms of ART-associated OI (points 2 and 3 in [B]). 
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Table 1 Pathogens and key clinical features of associated IRIS
Condition Clinical features of IRIS
Pathogen-associated
Bacteria
 Mycobacterium tuberculosis Fever, lymphadenitis, new/ worsening pulmonary infiltrates, pleural effusions, hepatomegaly, 
paradoxical or unmasking TBM/ tuberculoma
 NTM Fever, lymphadenitis (painful/suppurative), pulmonary infiltrates and cavitation, inflammatory masses
  Mycobacterium avium-intracellulare
  Mycobacterium genavense
  Mycobacterium kansasii
  Mycobacterium scrofulaceum
  Mycobacterium xenopi
  BCG Pediatric, vaccine associated; local reaction, lymphadenitis
  Mycobacterium leprae Typically tuberculoid or borderline forms, type 1 reactions, neuritis
 Other
  Bartonella spp. Granulomatous splenitis
  Chlamydia trachomatis Reiter’s syndrome
Viral
 Herpes viruses
  CMV Immune recovery uveitis (usually following previous history of retinitis), retinitis (typically unmasking)
  VZV Dermatologic reactivation (shingles), encephalitis, transverse myelitis, stromal keratitis
  HSV-1, HSV-2 Mucocutaneous ulceration, encephalomyelitis
  eBV New presentation of non-Hodgkins’s lymphoma, Burkitt’s lymphoma
  HHV-8 Kaposi’s sarcoma- IRIS, multicentric Castleman’s disease
 Hepatitis B, Hepatitis C Hepatitis flare, rapidly progressive cirrhosis
 Polyomaviruses
  JC virus Paradoxical PML (clinical deterioration, progression of lesions) or unmasking PML (new diagnosis)
  BK virus Meningoencephalitis
  Molluscumcontagiosum virus Acute new or recurrent cutaneous papules with florid/ extensive distribution
  Parvovirus B19 Pure red cell aplasia, encephalitis
  HPV warts (acute recurrence/ relapse or enlargement)
Fungal
  Cryptococcus neoformans Meningitis with raised intracranial pressure,lymphadenitis, pneumonitis, ocular and soft tissue 
inflammation
  Pneumocystis jirovecii Unmasking PCP, paradoxical deterioration during or shortly after treatment with worsening hypoxia 
and new pulmonary infiltrates, organizing pneumonia (rare)
  Histoplasma spp Acute fistulous lymphadenopathy
  Candida spp Typically unmasking; mucocutaneous (oral/oesophageal)
  Tinea corporis Inflammatory cutaneous presentation
Parasitic
  Toxoplasma gondii New or enlarging intracerebral lesions (ring-enhancing appearance on contrast neuroimaging)
  Schistosoma mansoni Eosinophilia, enteritis, colitis/polyposis
  Leishmania sp
   Leishmania major Cutaneous, uveitis
   Leishmania infantum Post-kala-azar dermal leishmaniasis, visceral leishmaniasis
   Leishmania braziliensis Cutaneous, mucosal
  Strongyloidesstercoralis Gastrointestinal or disseminated presentation; pneumonitis, enteritis, eosinophilia, hepatitis
  Cryptosporidium spp Terminal ileitis, duodenitis, cholangitis, gastrointestinal ulceration
  Microsporidium spp Keratoconjunctivitis
Non-pathogen-associated
 Autoimmune May occur as a new presentation, or an exacerbation of existing autoimmune condition
  Grave’s disease
  Guillain -Barré Syndrome
  Rheumatoid arthritis
  Polymyositis
  SLe
  Relapsing polychondritis
(Continued)
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example, individuals who develop C-IRIS have significantly 
reduced CSF inflammation during the initial episode of CM 
compared to non-IRIS patients (lower CSF white cell count, 
interferon-γ [IFN-γ], IL-6, IL-8, and TNF-α) and higher pre-
ART serum cryptococcal antigen titers.46,49 In TBM-IRIS, 
CSF culture positivity for Mycobacterium tuberculosis 
(M.tb) at TBM diagnosis confers a ninefold greater risk of 
IRIS, compared to those with culture-negative TBM, also 
suggesting that antigen load at OI diagnosis is important. 
However, in TBM, prior to ART initiation, higher TNF-α 
levels and raised CSF neutrophil counts were observed in 
IRIS patients compared to those that did not develop IRIS, 
suggesting that a pro- rather than anti-inflammatory milieu 
precedes TBM IRIS onset.51
As ART initiation leads to a rapid increase in peripheral 
blood CD4 T lymphocyte count in most patients, the recovery 
of pathogen-specific cell-mediated immune responses has been 
studied in TB and other OI, in HIV-infected patients following 
ART initiation. In HIV-infected patients, increased CD4 Th1 
responses to mycobacterial antigens have been reported fol-
lowing ART initiation.16,52–55 Studies indicate these increased 
responses associate with IRIS.16,52,53,55 However, a detailed 
longitudinal study of CD4 T-cell responses to a range of 
M.tb recombinant antigens found that highly dynamic IFN-γ 
responses occurred in both TB-IRIS patients and patients who 
did not develop IRIS and did not clearly differentiate the two 
groups.54 This finding has been supported by the results of two 
further studies of Th1 responses to mycobacterial antigens in 
TB-IRIS, which also call into question a causal link.56,57
While a disturbance of regulatory T-cell number or func-
tion could explain excessive inflammation, this has not been 
convincingly demonstrated. A few studies have demonstrated 
an increased rather than decreased number of regulatory CD4 
T-cells in mycobacterial and C-IRIS.54,58,59 Reduced IL-10 
has been associated with IRIS in some studies, suggesting 
that regulatory function may be impaired.58,60 However, a 
recent comparison of 20 TB-IRIS patients and 20 non-IRIS 
control patients found increased IL-10 concentrations in 
serum of TB-IRIS patients, and increased IL-10 transcript 
in peripheral blood mononuclear cells of TB-IRIS patients 
compared to controls, after restimulation with M.tb.61 One 
study demonstrated reduced numbers of inhibitory natural 
killer (NK) receptors on mycobacteria-specific Vδ2 TCRγδ 
T-cells.53 Further studies of regulatory cell types and function 
in IRIS are required.
Barber et al (studying a murine model of MAI-IRIS) 
argue that because IRIS is not specific to CD4 T-cell deple-
tion in HIV (and occurs following reversal of HIV-unrelated 
immunosuppression, eg, post-TNF-α treatment), it is unlikely 
that CD4 T-cell responses are the central contributory factor.62 
Rather, they propose that an uncoupling of innate and adaptive 
immunity is responsible. They hypothesize that in HIV infec-
tion, CD4 deficiency and thus deficiency of CD4 co-stimula-
tion impairs full activation of innate immune cells, particularly 
macrophages in TB and MAI infection. The resultant antigen 
accumulation and excessive priming of innate immune cells 
lead to an excessive inflammatory response, once activation 
does occur following immune restoration.62
Given their importance in antigen processing and pathogen 
trafficking, cells of the innate immune system such as mono-
cytes, macrophages, and neutrophils are of increasing interest 
in IRIS pathophysiology. Favoring a role for innate immunity 
is the formation of organized tissue granulomas in IRIS (such 
as granulomatous hepatitis in TB-IRIS). Granulomatous 
Table 1 (Continued)
Condition Clinical features of IRIS
 Dermatological Inflammatory presentation
  eosinophilic folliculitis
  Seborrheic dermatitis
  Pruritic papular eruption
  Acne
Other
  Sarcoidosis New or recurrent granulomatous inflammation, typically late (around 12 months post-ART initiation) 
in patients with CD4 counts .200 cells/mm3; typically pulmonary presentation, but may be cutaneous 
(erythema nodosum, papular lesions) and/or intra-abdominal
  Lymphoid interstitial pneumonitis Fever, respiratory distress, negative microbiological tests (may mimic PCP)
  CNS IRIS Leukoencephalopathy, demyelination, cerebral edema
Abbreviations: ART, anti-retroviral therapy; BCG, Bacillus Calmette–Guérin; CMV, cytomegalovirus; CNS, central nervous system; EBV, Epstein–Barr virus, HSV, Herpes 
simplex virus; HHV-8, Human herpes virus-8 (Kaposi’s sarcoma virus); HPV, human papilloma virus; IRIS, immune reconstitution inflammatory syndrome; JC, John Cunningham; 
NTM, nontuberculous mycobacteria; OI, opportunistic infection; PCP, Pneumocystis jirovecii pneumonia; PML, progressive multifocal leukoencephalopathy; SLE, systemic lupus 
erythematosus; TBM, tuberculosis meningitis; VZV, Varicella zoster virus.
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inflammation, which is notably absent in untreated advanced 
HIV, suggests enhanced macrophage activity during immune 
reconstitution.63 A fatal case of unmasking TB-IRIS associ-
ated with a pronounced macrophage-dominated pulmonary 
infiltrate on postmortem has been reported.64 Suppurative 
inflammation may develop in IRIS, which suggests heightened 
neutrophil activity.60,65 Several studies have reported increased 
inflammatory cytokines and chemokines of myeloid origin 
present at, and prior to, IRIS development, evident in serum 
and on restimulation of cells ex vivo with antigen.45,66,67 A cross-
sectional study of peripheral blood mononuclear cell responses 
reported elevated matrix metalloproteinase (MMP) transcripts 
in TB-IRIS patients compared to controls, accompanied by 
elevated serum concentrations of MMP-7.68 MMPs are host 
enzymes that are  upregulated in response to TB infection, mainly 
myeloid and epithelial cell derived and activated by proinflam-
matory cytokines.69–72 They are capable of breaking down and 
remodeling extracellular matrix, and may contribute to tissue 
damage in IRIS.
Two studies have examined NK cell function in TB-IRIS. In 
a study of unmasking IRIS, these cells were found to express 
increased activation markers73 In a longitudinal study, NK 
cells isolated from paradoxical TB-IRIS patients had higher 
expression of CD107a, a degranulation marker, than non-IRIS 
controls, prior to IRIS onset.74 The authors hypothesized that 
increased NK cell-mediated lysis of M.tb-infected cells may 
increase antigen load.74
In summary, recent evidence suggests that innate immune 
dysfunction in the context of high antigen load plays a role 
in driving pathological proinflammatory responses in IRIS. 
The role of pathogen-specific cell-mediated immunity and 
regulatory mechanisms are less clear (see Figure 2). Studies 
of patients are frequently limited by small sample size and 
examination of peripheral blood rather than tissue immune 
responses. Development of animal models of IRIS may better 
allow dissection of precise pathophysiological mechanisms, 
which may differ for paradoxical and unmasking IRIS, and 
for different forms of pathogen-associated IRIS.75
Clinical manifestations
The time of onset of IRIS symptoms is variable, but is typically 
from a few days to 6 months after ART initiation. Although 
presentation varies by associated pathogen, a common feature 
is that onset is usually acute and there are features of inflam-
mation, which may be generalized (eg, fever, tachycardia) or 
Table 2 Recently published studies reporting IRIS incidence rates 
in unselected cohorts
Population  
and reference
Overall  
incidence, %
IRIS-associated condition/ 
opportunistic infection,  
proportion of total IRIS cases, %
USA35 
n=196
11 (reported  
on paradoxical  
IRIS only)
KS, 57 
TB, 19 
PCP, 14 
Disseminated cryptococcosis, 5 
MAI, 5
USA21 
n=2,610
10.6 (reported  
on unmasking  
IRIS only)
Candidiasis, 23 
Folliculitis, 13.8 
HSV, 12.4 
warts, 12.2 
Tinea, 11.1
Mexico36 
n=390
27 VZV, 32 
TB, 11 
MAI, 9 
PCP, 6 
Cryptococcus neoformans, 5
India37 
n=97
35 Mucocutaneous (combined), 35.2 
TB, 29.4 
PCP, 17.6 
CMV retinitis, 5.9 
CM, 5.9 
MAI, 5.9
Mozambique38 
n=136
26.5 Tinea, 25 
KS, 22.2 
TB, 16.7 
PCP/pneumonitis, 8.3 
HSV, 8.3
South Africa7 
n=498
22.9 Folliculitis, 27.3 
TB, 24.4 
HSV, 9.4 
VZV, 6.5 
warts, 7.2
Note: The most common IRIS-associated conditions are listed, with proportion of 
IRIS attributed.
Abbreviations: CM, cryptococcal meningitis; CMV, Cytomegalovirus; HSV, 
herpes simplex virus; IRIS, immune reconstitution inflammatory syndrome; KS, 
Kaposi’s sarcoma; MAI, Mycobacterium avium-intracellulare; PCP, Pneumocystis jirovecii 
pneumonia; TB, tuberculosis; VZV, Varicella zoster virus.
Table 3 Risk factors for HIV-associated IRIS
Risk factor
Host-related Low CD4 count at initiation of ART
Opportunistic infection or TB prior to ART 
initiation
Genetic predisposition: eg, HLA-A, -B44, -DR4 
(associated with herpes virus IRIS); 
TNFA-308*1, IL6-174*G (associated with 
mycobacterial IRIS)
Paucity of immune response at OI diagnosis  
(in the case of C-IRIS)
Pathogen-related Degree of dissemination of OI/burden of 
infection (eg, TB, KS, cryptococcosis)
High pre-ART HIV viral load
Treatment-related Shorter duration of OI treatment prior to 
starting ART (paradoxical IRIS)
Rapid suppression of HIV viral load
Abbreviations: ART, antiretroviral therapy; C-IRIS, cryptococcal-associated IRIS; 
IRIS, immune reconstitution inflammatory syndrome; KS, Kaposi’s sarcoma; OI, 
opportunistic infection; TB, tuberculosis.
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localized (eg, lymphadenitis). In paradoxical IRIS, symptoms 
of the previously diagnosed OI may recur or worsen, but a 
clear improvement is usually reported after the start of OI 
treatment prior to starting ART (see Figure 1). The original 
descriptions of MAI-IRIS reported that mycobacteraemia, 
which was typical of MAI in advanced HIV pre-ART, was 
not typical of MAI-IRIS, which was characterized by focal 
lymphadenitis and paucity of bacteria. In severe forms of 
IRIS (eg, TB-IRIS, CMV immune restoration uveitis, and 
C-IRIS), paucity of viable pathogen is characteristic at the 
time of IRIS, despite severe inflammation. Clinical features 
associated with different forms of IRIS are summarized in 
Table 1 and described in more detail in subsequent sections.
Management and prevention of IRIS
As IRIS is antigen-driven, optimization of treatment of the 
underlying OI is an important aspect of treatment in many 
forms of IRIS (see following sections on KS-IRIS and 
C-IRIS), in order to quickly reduce pathogen load.76 Sup-
portive management may be required, including intravenous 
fluids and oxygen.77 ART is key to eventual immune recovery 
and we recommend that ART should not be interrupted unless 
there is concern about concurrent drug toxicity, in which case 
ART substitution is preferable. There has been no trial of ART 
cessation in management of IRIS. ART interruption may also 
be considered in severe, life-threatening cases of CNS IRIS, 
in patients with a depressed level of consciousness. However, 
the undesirable effects of stopping ART include a risk of 
further OI and the emergence of ART resistance.
Various anti-inflammatory agents have been used in 
treatment of paradoxical and unmasking IRIS, including 
corticosteroids and nonsteroidal anti-inflammatory drugs 
(NSAIDs). A  randomized controlled trial of oral prednisone 
for paradoxical TB-IRIS showed benefit, and this is discussed 
in more detail in the section on TB-IRIS. Use of corticoster-
oids in other forms of IRIS is based solely on expert opinion. 
Systemic corticosteroid use is associated with a number of 
potential adverse effects in HIV, including infective compli-
cations, such as reactivation of herpes virus infections, KS 
progression, and mucocutaneous candidiasis.76,78,79 Addition-
ally, noninfective conditions are associated with chronic oral 
corticosteroid use, including hyperglycemia, hypertension, 
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Figure 2 A conceptual model of immune reconstitution inflammatory syndrome (IRIS) pathophysiology with three key features represented in central rectangles.
Notes: Excess antigen is a feature of tuberculosis (TB) IRIS, cryptococcal IRIS and Kaposi’s sarcoma IRIS. This may result from extreme immunosuppression prior to 
antiretroviral therapy (ART) initiation, which increases the risk of opportunistic infection (OI) dissemination (in TB), and is associated with paucity of inflammation in 
cryptococcal meningitis (CM), especially in those patients who go on to develop IRIS. Antigen is likely to be more abundant if the OI is untreated, or if treatment has recently 
started. Immune cell dysfunction following ART has been described in IRIS, although the mechanism of this is incompletely understood. It may involve uncoupling of innate 
and acquired immune responses, restoration of exuberant pathogen-specific cellular responses, and defective or delayed regulatory responses. An excess of proinflammatory 
cytokines has been associated with TB-IRIS, and cryptococcal IRIS, in blood and cerebrospinal fluid. Possible relationships between the three key components are depicted 
by differentially weighted arrows. However, the direction of causality is not clear. It is probable that the presence of high antigen in IRIS drives proinflammatory cytokine 
responses directly through stimulation of innate immune responses and indirectly when adaptive immunity recovers. Further studies are required to improve understanding 
of these interactions.
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osteoporosis, and gastrointestinal ulceration. Therefore, 
aside from cases of TB-IRIS, systemic corticosteroids are 
recommended for more severe forms of IRIS inflammation, 
in the absence of contraindications, and more commonly 
for mycobacterial and fungal-associated IRIS than for viral-
associated IRIS. Periocular or intravitreal corticosteroids have 
been used to treat immune restoration uveitis.80 NSAIDs are 
used in milder forms of IRIS, and are not associated with 
reactivation of other infections, but their efficacy has not 
been tested by clinical trials. Gastrointestinal irritation and 
nephrotoxicity are a concern in chronic NSAID usage.
Adjunctive oral corticosteroids are routinely prescribed 
with TB treatment for certain forms of TB (pericardial and 
CNS TB). TBM-IRIS may develop despite corticosteroid 
therapy.51 The principles of IRIS prevention include optimal 
prophylaxis of OI in advanced HIV (eg, cotrimoxazole to 
prevent Pneumocystis jirovecii pneumonia [PCP]), optimal 
screening for subclinical OI prior to ART initiation (eg, for 
serum cryptococcal antigen in patients with CD4 ,100), 
reduction of risk factors for IRIS where possible (see 
Table 3), and optimal timing of ART initiation informed 
by clinical trial data for that pathogen (see discussion on 
TB-IRIS and C-IRIS in following sections).
In the next section, we examine in more detail three 
common and clinically important forms of IRIS, highlight-
ing clinical features, pathophysiology, and management 
issues. We then briefly discuss other common forms of IRIS. 
Reviews of pulmonary and CNS manifestations of IRIS and 
IRIS management have recently been published.25,76,81,82 The 
clinical characteristics of TB-IRIS and C-IRIS are summa-
rized in Table 4.
TB-IRIS
TB-IRIS is among the commonest forms of IRIS given the 
global distribution of TB infection (Table 2). Paradoxical 
TB-IRIS was reported to occur in 15.7% (95% credibility 
interval 9.7%–24.5%) of TB patients starting ART in the 
previously described meta-analysis by Müller et al,9 which 
reported on 16 studies of TB-IRIS, although higher rates are 
reported in some settings.9,83 For example, in a recent Indian 
study, an incidence of 54.2% was reported in patients with 
culture-confirmed pulmonary TB and a South African study 
reported 47% incidence of paradoxical TB-IRIS in patients 
with TBM.51,84 In South Africa, where more than 60% of TB 
patients are HIV coinfected, this translates into a consider-
able disease burden.85
Both paradoxical and unmasking forms of TB-IRIS 
are now widely reported, although paradoxical IRIS has 
been more extensively studied.28,83,86 Paradoxical TB-IRIS 
typically presents in pulmonary TB cases as a recurrence 
or worsening of respiratory symptoms (cough or shortness 
of breath), associated with a recurrence or worsening of 
Table 4 Clinical characteristics of TB-IRIS and C-IRIS
TB-IRIS  C-IRIS
Incidence 2%–54% 13%–45%
Key risk factors Shorter duration from TB treatment initiation to ART  
initiation 
Disseminated TB at diagnosis 
Low CD4 count prior to ART
Markers of fungal burden 
• Fungemia 
• Higher CrAg titer 
Lack of CNS inflammation prior to ART
Onset ,3 months 
Median 14 days
,12 months 
Median 4–9 weeks
Differential  
diagnosis
Drug-resistant TB 
Drug toxicity 
Another OI 
Poor adherence to therapy
Relapse of CM 
Fluconazole resistance 
Another OI
Key investigations Cultures/molecular testing for drug resistance  
(eg, GeneXpert on sputum, CSF culture if CNS symptoms) 
Consider other infections (eg, unmasking OI)
CSF fungal culture: CSF may not be culture-negative, 
especially where fluconazole monotherapy is used for 
treatment of CM 
Positive fungal culture after 3 months of antifungal 
therapy likely indicates treatment failure rather than IRIS 
Note: CrAg titers (serum or CSF) are not helpful
Treatment Prednisone 1.5 mg/kg for 14 days, followed by 0.75 mg/kg  
for 14 days or reduced according to clinical response
No evidence to support steroid use 
Optimize/strengthen antifungal therapy 
Therapeutic lumbar punctures to relieve raised 
intracranial pressure 
Steroids if severe or refractory
Abbreviations: ART, antiretroviral therapy; C-IRIS, cryptococcal-associated IRIS; CM, cryptococcal meningitis; CNS, central nervous system; CrAg, cryptococcal antigen; 
CSF, cerebrospinal fluid; IRIS, immune reconstitution inflammatory syndrome; OI, opportunistic infection; TB, tuberculosis; TB-IRIS, tuberculosis-associated IRIS.
HIV/AIDS – Research and Palliative Care 2015:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
57
HIV-associated IRIS
constitutional symptoms (weight loss, night sweats, fever), 
and not uncommonly new or expanding infiltrates on chest 
radiograph, as shown in Figure 3.87 Paradoxical IRIS may 
occur at any disease site, including lymph nodes, which 
typically manifests with rapid enlargement followed by 
suppuration.76 CNS TB-IRIS typically presents with new or 
worsening meningitis and/or features of raised intracranial 
pressure, due to enlarging cerebral tuberculomas or intrac-
ranial abscesses, with a high mortality.42,82,88 It may also 
present with epidural abscesses, spondylitis, and radicu-
lomyelopathy.51,88 Hepatosplenic (typically granulomatous 
disease leading to hepatitis and/or appearance of microab-
scesses), abdominal (eg, lymphadenopathy, peritonitis), 
and musculoskeletal (eg, mono- or polyarthritis) features 
are not infrequent.83 Extrapulmonary TB-IRIS manifesta-
tions may occur in patients who originally presented with 
pulmonary TB, and vice versa. Accompanying laboratory 
features usually include a raised CRP, and may include 
worsening anemia.
The differential diagnosis of TB-IRIS includes other new 
infections (eg, pneumonia, influenza), unmasking of other OI 
(eg, PCP), drug reactions (eg, pyrazinamide arthropathy), and 
multidrug-resistant TB.89 In resource-limited settings, where 
M.tb drug-susceptibility testing is not routinely available, 
the latter is difficult to exclude. Additionally, TB-IRIS may 
occur in cases of drug-resistant TB.89 There is no laboratory 
test for TB-IRIS and exclusion of differential diagnoses with 
certainty can be very challenging in practice.
The only randomized placebo-controlled trial of treatment 
of IRIS was conducted in patients with paradoxical TB-IRIS, 
in South Africa.90 One hundred and ten patients were enrolled 
with a median CD4 count of 116 cells/mm3 and paradoxical 
TB-IRIS diagnosed according to INSHI criteria19, limited to 
those with increasing infiltrates on chest radiograph,  enlarging 
lymph nodes, serous effusion, or cold abscess. Patients with 
 immediately life-threatening manifestations of TB-IRIS 
(respiratory failure, altered level of consciousness, new focal 
neurological sign/s, or compression of a vital structure) were 
excluded from the study. The intervention arm (n=55) consisted 
of prednisone 1.5 mg/kg/day for 14 days, reduced to 0.75 mg/
kg/day for a further 14 days. This led to a reduction in the 
composite primary endpoint of days of hospitalization and 
outpatient therapeutic procedures (median per patient 0 versus 
3 in placebo arm, P=0.04). There was also more rapid improve-
ment in symptom scores and chest radiographs in prednisone, 
compared to placebo-treated, patients. There were more mild 
infections (eg, oral candidiasis) in the prednisone-treated arm, 
but no excess of severe infections. There were no significant 
differences in possible drug-related side effects reported in 
each arm. These data support use of prednisone in TB-IRIS, 
for moderate and severe cases. Unfortunately, TB-IRIS symp-
toms may recur following steroid withdrawal, requiring longer 
courses of treatment.90,91 Other immunomodulatory therapies 
have been considered in management of TB-IRIS, with case 
reports of favorable outcomes with thalidomide and montelu-
kast, but none has been tested in randomized controlled trials 
(RCTs).76,77,92,93
Strategies for TB-IRIS prevention have focused on optimiz-
ing the timing of ART initiation, after it was observed that a 
shorter time between TB treatment initiation and ART initiation 
increased TB-IRIS risk. Three RCTs that studied the optimal 
timing of ART in TB patients have informed practice.94–96 
These trials demonstrated that in patients with a CD4 count 
,50 cells/mm3, starting ART around 2 weeks after TB treat-
ment reduced mortality or a combined endpoint of mortality 
and AIDS progression. Thus, while commencing ART earlier 
is associated with increased IRIS risk, the survival benefit in 
these patients with low CD4 counts overrides this. However, 
Figure 3 This series of three chest radiographs demonstrates features of paradoxical tuberculosis (TB) immune reconstitution inflammatory syndrome in a 21-year-old 
antiretroviral therapy (ART)-naïve patient, with CD4 count 34 cells/mm3, who was diagnosed with drug-sensitive pulmonary TB on sputum culture.
Notes: At TB diagnosis, chest radiograph showed bilateral hilar and mediastinal lymphadenopathy, right middle and right upper lobe infiltrates, and a right-sided pleural 
effusion (A). These abnormalities improved with TB therapy (B) and 10 weeks later ART was initiated. Nine days following ART initiation, she presented with recurrence 
of cough, right-sided chest pain, fatigue, and weight loss. On examination, tachycardia, tachypnea, and tender hepatomegaly were observed. CD4 count had increased to 
161 cells/mm3. Chest radiograph showed a marked deterioration, particularly of the right-sided pulmonary infiltrates, which became more extensive than at the time of initial 
presentation with TB (C).
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in patients with CD4 .50 cells/mm3, ART can be commenced 
between 2 and 8 weeks post-TB treatment, and delaying to 8 
weeks is not associated with excess mortality, but may reduce 
IRIS risk. A recent placebo-controlled study of ART timing in 
smear-positive pulmonary TB patients with CD4 count .220 
cells/mm3 demonstrated no benefit in a combined endpoint 
of TB treatment failure, TB recurrence, and mortality, when 
ART was commenced at 2 weeks post-TB treatment initiation, 
compared to delaying until after TB treatment was completed. 
IRIS rates were similar in the early and late arms (10%).97 A 
single RCT of ART timing in TBM demonstrated no survival 
benefit from starting ART within 7 days of commencing TB 
therapy, compared to following 2 months of TB treatment, and 
an increased probability of serious adverse events.98 As a result, 
it is recommended that ART initiation be delayed until 8 weeks 
after TB therapy is commenced in TBM patients.43
In environments with a high incidence of both TB infection 
and HIV infection, a significant proportion of undiagnosed 
TB may be diagnosed by routine screening of all HIV-infected 
patients entering care, by sputum culture or GeneXpert (the 
latter being less sensitive), even those who are asymptomatic. 
Isoniazid preventive therapy may be indicated for those who 
do not have active disease. Strategies such as these are likely 
to reduce the prevalence of undiagnosed TB in patients starting 
ART and thus may reduce risk of unmasking TB-IRIS.65 This 
could be performed alongside ART counseling, but should not 
unnecessarily delay commencement of ART in immunosup-
pressed patients. There are considerable logistic and financial 
challenges to implementing such a strategy in programmatic 
settings. The World Health Organization currently recom-
mends an approach based on symptom screening, to identify 
active TB in HIV-infected individuals, in resource-constrained 
settings.85 However, the performance of this strategy varies 
across different clinical settings.99
There have been no successful trials of preventive strat-
egies for paradoxical TB-IRIS, although two randomized 
placebo-controlled trials for paradoxical TB-IRIS  prevention 
are currently under way in South Africa. A randomized 
placebo-controlled trial of prednisone for TB-IRIS preven-
tion in high-risk patients is recruiting patients in Cape Town 
(NCT01924286). The TB-IRIS NSAID Cox-2  Inhibitor 
Prevention Trial is investigating meloxicam for TB-IRIS 
prevention (NCT02060006).
Cryptococcal IRIS
Paradoxical C-IRIS is reported to occur in 13%–45% of HIV-
infected persons who start ART after treatment for CM. It 
occurs a median of 4–9 weeks following ART initiation but 
delayed cases have been reported up to a year after initia-
tion of ART.46,100–102 The usual presentation is a recurrence 
of meningitis symptoms (headache, nuchal rigidity, visual 
disturbance, and vomiting) along with other CNS signs, 
such as raised intracranial pressure, impaired consciousness, 
seizures, and focal neurology. Non-neurological presentations 
are less commonly described but include lymphadenitis, 
pneumonitis, and eye and soft tissue disease.18
As with other neurological forms of IRIS, C-IRIS causes 
substantial morbidity and mortality (13%–36%) and is an 
independent predictor of death in CM patients starting ART.46 
The risk of developing C-IRIS is increased in individuals who 
have high CSF fungal burdens during the initial episode of 
CM, and in those who fail to clear the infection prior to the 
initiation of ART.103 In one study, lower pre-ART CD4 count 
was also associated with increased risk of C-IRIS.104
Diagnosis of paradoxical C-IRIS is based on INSHI 
criteria with diagnostic workup targeted at excluding other 
causes.18 In patients presenting with recurrent meningitis 
symptoms, a lumbar puncture should be performed and the 
opening pressure measured; CSF should be sent for bacterial, 
mycobacterial, and fungal culture to exclude relapsed CM 
and an alternative cause of meningitis.76
As there have been no clinical trials, management of 
suspected paradoxical C-IRIS is based solely on expert 
opinion. Reduction of pathogen load is an underlying objec-
tive and cryptococcal treatment should be optimized. Raised 
intracranial pressure can be controlled with therapeutic CSF 
drainage by lumbar puncture (repeated daily if necessary). 
Corticosteroids can be considered in severe cases, prefer-
ably once other etiologies are excluded and CSF fungal 
culture result is known to be negative. In patients with 
life-threatening neurological deterioration, steroids should 
be started immediately while simultaneously treating with 
amphotericin B to cover the possibility of a cryptococcal 
relapse.76
The timing of ART initiation in patients with CM has been 
examined in four trials to date.105,107–109 The first recruited 282 
patients, mainly from USA, with a variety of AIDS-related OI, 
of which 12% had CM.105 The overall trial result showed that 
early ART (within 14 days of OI treatment) was associated 
with a reduced likelihood of AIDS progression or death, com-
pared to ART initiation after OI treatment completion, with 
no excess risk of IRIS. When the CM patients were analyzed 
separately, the point estimate showed a trend toward improved 
outcome in the early arm.105,106 A small study of CM patients 
in Botswana (n=27) compared early ART (within 7 days) with 
deferred ART (after 28 days), using intravenous amphotericin 
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B as antifungal treatment. Similar to the US study, no differ-
ence in mortality was noted; however, early ART was associ-
ated with significantly increased IRIS risk.107
An open-label randomized trial in Zimbabwe was con-
ducted comparing ART within 72 hours of CM treatment 
initiation (fluconazole 800 mg per day) with ART initiation 
after 10 weeks.108 The trial was stopped early by the data 
safety monitoring board after excess deaths were noted in the 
early treatment arm, mainly during the first 2 weeks of ART. 
The authors suggested IRIS to be the likely cause.108
The Cryptococcal Optimal ART Timing (COAT) trial 
was conducted to definitively address the question of when 
to start ART in CM, using amphotericin B-based anticryp-
tococcal therapy.109 This was an open-label randomized trial 
conducted in Uganda and South Africa. ART-naïve patients 
with a first episode of CM were randomized to early ART 
initiation (7–14 days after starting amphotericin), or deferred 
(after 5 weeks). This trial was also stopped early by the data 
safety monitoring board after significantly increased mortal-
ity was noted in the early ART arm (6-month mortality 45% 
versus 30%, hazard ratio 1.7; 95% confidence interval [CI]: 
1.1–2.8; P=0.03).109 The explanation for this excess mortality 
was not clear; excess deaths all occurred within a month of 
starting ART, but reported rates of IRIS were not statistically 
different between the two study arms, nor was drug toxicity. 
Specific risk factors for death during early ART included 
altered mental status at time of randomization (hazard 
ratio 3.0; 95% CI: 1.0–8.8) and failure to mount a cellular 
response in the CSF (CSF white cell count ,5 cells/mm3) 
(hazard ratio 3.3; 95% CI: 1.3–8.4).109 Given that paucity of 
CSF inflammatory response has previously been associated 
with failure to sterilize the CSF and increased risk of IRIS, 
it seems plausible that immunopathology may underlie these 
excess deaths. Following these trials, guidelines for CM 
now suggest clinicians wait 4–6 weeks after commencing 
amphotericin B-based CM treatment, before ART is initiated 
in CM patients.110
In addition to paradoxical C-IRIS, presentation with 
a new diagnosis of CM shortly after starting ART is also 
well described, occurring in up to 1% of patients starting 
ART and in up to 33% of those who have a cryptococcal 
antigenemia at time of ART initiation.17,111–116 However, 
whether this occurs due to a persisting immune deficiency 
or an unmasking C-IRIS can be difficult to determine 
and has not been widely studied. INSHI provide case 
definitions for both ART-associated CM and unmasking 
C-IRIS and suggest unmasking C-IRIS should be con-
sidered if there are “unusual, exaggerated, or heightened 
inflammatory manifestations” (eg, CSF white cell count 
.50 cells/µL, persistently raised intracranial pressure refrac-
tory to therapy, rapidly expanding CNS lesion, painful or 
suppurating lymphadenopathy, pneumonitis, granulomatous 
inflammation on histology).18
Persons who develop such ART-associated cryptococ-
cosis should be managed in the same way as patients not 
taking ART: potent antifungal therapy to reduce antigen load 
seems intuitive, and therapeutic lumbar puncture to control 
raised intracranial pressure is frequently required for the life-
threatening complication of raised intracranial pressure.117
KS-related IRIS
KS is an HIV-associated malignancy that is driven by 
replication of human herpes virus-8 (HHV-8), occurring 
most commonly in regions where there is high prevalence 
of HHV-8. It is the commonest malignancy associated with 
HIV infection.118 Patients typically present with localized 
or extensive mucocutaneous, hyperpigmented lesions, often 
with edema, most commonly affecting the skin but also 
frequently the oral mucosa. As a malignancy of lymphatic 
endothelium, it is capable of causing disseminated disease 
and may affect the lungs and gastrointestinal tract.119 No 
specific anti-HHV-8 agent has been shown to be effective, 
so treatment is limited to reversal of immune suppression 
with ART and cytotoxic chemotherapeutic agents when 
disease is extensive.
Paradoxical KS-IRIS occurs when ART is initiated in 
7%–31% of cases. This variation is probably related to differ-
ences in severity of KS, degree of immunosuppression, and 
treatment availability in different settings.40,120,121 KS-IRIS 
frequently presents with inflammation or enlargement of an 
existing KS lesion and/or worsening edema. Alternatively, 
during IRIS, KS may extend or appear rapidly at new ana-
tomical sites. Symptoms and signs vary according to the site 
of the KS lesion. Acute airway obstruction may occur and 
can be life-threatening.79 Significant gastrointestinal bleed-
ing may occur. Rapid extension of pulmonary lesions, may 
mimic an infective pulmonary process.25 Onset is between 
1 and 22 weeks, and usually in the first 12 weeks post-ART 
initiation.40,120,122
Little is known about the pathogenesis of KS-IRIS. 
Proinflammatory and Th1 cytokines are considered to be 
important in KS pathogenesis.123 Increased KS-IRIS risk is 
associated with use of ART alone as initial KS treatment, 
more extensive baseline KS tumor stage, baseline plasma 
HIV-1 RNA more than 105 copies/mL, and baseline detect-
able plasma HHV-8 DNA.40
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Treatment for KS-IRIS includes systemic chemotherapy 
and supportive measures, eg, radiotherapy should airway 
obstruction occur. Liposomal anthracyclines (eg, doxoru-
bicin) are the preferred first-line chemotherapeutic agents 
for KS and may be indicated in KS-IRIS where available. 
Corticosteroids may be harmful as there is an association with 
acute progression of KS lesions, possibly due to a permissive 
effect on HHV-8 viral replication.79 ART should be continued. 
Use of systemic chemotherapy for extensive disease prior to 
ART initiation may help prevent KS-IRIS, but this has not 
been systematically studied.
Mucocutaneous IRIS
Mucocutaneous conditions caused by viruses, such as herpes 
simplex virus causing genital ulceration, varicella zoster virus 
reactivation, molluscum contagiosum virus, and human papil-
loma virus, in addition to mucocutaneous fungal infections 
(eg, candida, tinea) collectively form the most common type 
of IRIS reported in many series (see Table 2).21,36–38 Other 
cutaneous manifestations include worsening of pruritic 
papular eruption and acne flares.7,21 Management typically 
involves targeting the causative organism where a treatment 
is available (eg, acyclovir for herpes simplex virus) and 
symptomatic treatment. No evidence-based guidelines are 
available. Although common and distressing for patients, 
these forms of IRIS are rarely severe.
CNS IRIS
CNS IRIS contributes the bulk of IRIS mortality.81 In addi-
tion to C-IRIS and TBM-IRIS (discussed above), progressive 
multifocal leukoencephalopathy (PML) IRIS and, less com-
monly, IRIS-associated with cerebral toxoplasmosis, have 
been described.24,26 PML-IRIS has been reviewed in detail 
recently by Post et al, who highlight a role for neuroimag-
ing in PML-IRIS diagnosis, with contrast enhancement of 
lesions and mass effect due to interstitial edema in PML-
IRIS, not typically found in PML.124 Neuroimaging is not 
available in many settings and autopsy studies suggest that 
PML is underdiagnosed, so it is probable that PML-IRIS is 
also underdiagnosed.125 Corticosteroids are used in cases of 
PML-IRIS, although there are no RCT data to support this. 
A recently published case report described use of maraviroc, 
a CCR5 antagonist, in an HIV-uninfected patient with PML-
IRIS, with a favorable outcome, but efficacy has not yet been 
assessed in a clinical trial.126
CNS IRIS has also been described in cases with no evi-
dence of an OI, where it is hypothesized that the reconstituting 
immune response targets CNS HIV proteins or alternatively 
host antigens, the latter an autoimmune process.127,128 A CD8 
(rather than a CD4) lymphocyte infiltration in the perivascular 
spaces characterizes this condition. Significant mortality is 
reported. Corticosteroids have been used in some cases, with 
favorable outcome.129
HIV-associated IRIS – other 
infectious causes
A wide variety of infectious pathogens have been linked to 
HIV-associated IRIS (Table 1). CMV reactivation is associ-
ated with advanced immune suppression (CD4 count below 
50 cells/mm3), most commonly causing retinitis, which may 
lead to permanent visual impairment. Immune restoration 
uveitis may occur following ART initiation in such patients 
and can be sight-threatening. In HIV–hepatitis B virus 
coinfected patients, an acute hepatitis flare (with potentially 
fulminant course) may occur post-ART initiation, and may be 
difficult to distinguish from ART drug toxicity.130 P. jirovecii 
is a common fungal cause of IRIS. Calligaro et al have 
reviewed PCP-IRIS and other pulmonary IRIS manifesta-
tions in more detail.25 Lawn has reviewed 24 cases of IRIS 
associated with parasitic infections, including Schistosoma 
mansoni, Strongyloides stercoralis, Leishmania spp., and 
Toxoplasma gondii.26
Summary and conclusion
Access to ART is improving worldwide, but because many 
patients still commence ART with low CD4 counts, IRIS 
remains a common complication. IRIS is a heterogeneous 
condition with a number of case definitions in use. Clinical 
manifestations and epidemiology are well described for some 
forms of IRIS, but specific diagnostic tests and evidence-
based treatment strategies are lacking. CNS IRIS is associated 
with a high mortality and requires more effective interven-
tions. While ART initiation causes IRIS, it is key to recovery 
of immune function and improved health outcomes, therefore 
delay or discontinuation of ART due to IRIS is not usually 
recommended. A notable exception is in patients with CM, in 
whom ART should be delayed until 4–6 weeks after CM treat-
ment initiation. Prevention strategies include: 1) treatment of 
HIV before advanced immunosuppression develops; 2) OI 
prevention in advanced HIV; 3) screening for and treatment 
of OI prior to ART initiation; and 4) optimal timing of ART 
initiation (this varies according to pathogen and CD4 count 
and takes into account mortality and IRIS risk). Treatment of 
IRIS involves optimal treatment of the underlying pathogen 
to reduce antigen load; supportive measures; and, in some 
cases, immunosuppression with corticosteroids.
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Key knowledge gaps in the diagnosis and treatment of 
IRIS exist. There are no standardized clinical case defini-
tions for many forms of IRIS (TB-IRIS and C-IRIS being 
the exceptions). Confirmatory diagnostic tests are lacking 
for all forms of IRIS. Most forms of IRIS lack evidence-
based management strategies, the use of prednisone in 
TB-IRIS being the exception. For all forms of IRIS, other 
immunomodulatory therapies have not been systematically 
studied. The specific cell phenotypes and inflammatory and 
regulatory pathways that are central in the development of 
IRIS, in the context of an abundance of foreign antigen, need 
to be more clearly defined. Improved understanding of the 
pathophysiology of IRIS will hopefully enable improved 
diagnostic modalities and better targeted treatments to be 
developed.
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